Tivozanib (VEGFR TKI)

FOTIVDA┬« (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2 AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models.3 Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new formulation by KKC in wet acute macular degeneration.

VEGF In Solid Tumors

The vascular endothelial growth factor (VEGF) pathway plays a significant role in angiogenesis, which is critical in cancer. Angiogenesis, the formation of new blood vessels, is essential for endothelial cell proliferation, migration and survival. There are five known VEGF ligands (A, B, C, D, PLGF) and three VEGF receptors (1, 2 and 3). Each ligand exhibits distinct but overlapping binding profiles for the three VEGF receptors.

tivozanib_moa_graphic
click to enlarge

To optimally inhibit the VEGF pathway it may be critical to effectively block all three VEGF receptors as each plays an important role in cancer angiogenesis:

  • VEGF receptor 1 is critical for the modulation of endothelial cell survival and vessel morphogenesis;
  • VEGF receptor 2 is thought to be the predominant receptor for endothelial cell proliferation and migration; and,
  • VEGF receptor 3 promotes endothelial sprouting and vascular network formation.

Preclinical studies have demonstrated tivozanib is a potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

For more information, please visit FOTIVDA

1Fotivda (Tivozanib) SmPC August 2017
2Motzer RJ, Nosov D, Eisen T, et al. J Clin Oncol 2013; 31(30): 3791-9.
3Pawlowski N et al. AACR 2013. Poster 3971